Allworth Financial LP Sells 162 Shares of Cencora, Inc. $COR

Allworth Financial LP lessened its stake in shares of Cencora, Inc. (NYSE:COR) by 6.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,556 shares of the company’s stock after selling 162 shares during the quarter. Allworth Financial LP’s holdings in Cencora were worth $767,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Invesco Ltd. boosted its stake in shares of Cencora by 42.1% in the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after buying an additional 1,364,433 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Cencora by 4,459.6% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock valued at $277,321,000 after buying an additional 975,362 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Cencora by 8.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares in the last quarter. Nuveen LLC bought a new stake in shares of Cencora during the first quarter valued at about $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec lifted its stake in Cencora by 144.4% in the 1st quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock worth $206,641,000 after purchasing an additional 439,008 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Activity

In related news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 41,544 shares of company stock worth $12,230,941. Company insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Mizuho raised their price target on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Robert W. Baird increased their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Finally, JPMorgan Chase & Co. boosted their price target on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Price Performance

COR opened at $361.97 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market cap of $70.18 billion, a P/E ratio of 37.24, a PEG ratio of 1.56 and a beta of 0.63. The business has a fifty day moving average of $321.35 and a 200 day moving average of $302.08. Cencora, Inc. has a 52-week low of $223.92 and a 52-week high of $369.00.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the business posted $3.34 EPS. Cencora’s quarterly revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.